Preclinical studies in an in vivo non-small cell lung cancer model demonstrated improved anti-tumour activity when adding encelimab to dostarlimab, an anti-PD-1 antibody approved for the treatment of dMMR advanced solid tumours [24–26]. Here, PDCD1 is linked to neoplasm.